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Single-cell analysis reveals IGF-1 
potentiation of inhibition of the 
TGF-β/Smad pathway of fibrosis in 
human keratocytes in vitro
Tomislav Sarenac1,2, Martin Trapecar2,3, Lidija Gradisnik2, Marjan Slak Rupnik2,4 & 
Dusica Pahor1,2
Corneal wound healing is often affected by TGF-β–mediated fibrosis and scar formation. Guided fibrosis 
with IGF-1 and antifibrotic substances might maintain corneal transparency. Primary human corneal 
keratocytes under serum-free conditions were used as a model of corneal stromal wounding, with 
markers of corneal fibrosis and opacity studied under TGF-β2 stimulation. Single-cell imaging flow 
cytometry was used to determine nuclearization of Smad3, and intracellular fluorescence intensity of 
Smad7 and the corneal crystallin aldehyde dehydrogenase 3A1. Extracellular matrix proteoglycans 
keratocan and biglycan were quantified using ELISAs. On the TGF-β2 background, the keratocytes 
were treated with IGF-1, and suberoylanilidehydroxamic acid (SAHA) or halofuginone ± IGF-1. IGF-1 
alone decreased Smad3 nuclearization and increased aldehyde dehydrogenase 3A1 expression, with 
favorable extracellular matrix proteoglycan composition. SAHA induced higher Smad7 levels and 
inhibited translocation of Smad3 to the nucleus, also when combined with IGF-1. Immunofluorescence 
showed that myofibroblast transdifferentiation is attenuated and appearance of fibroblasts is favored 
by IGF-1 alone and in combination with the antifibrotic substances. The TGF-β/Smad pathway of fibrosis 
and opacity was inhibited by IGF-1, and further with SAHA in particular, and with halofuginone. IGF-1 
is thus a valid aid to antifibrotic treatment, with potential for effective and transparent corneal wound 
healing.
One of the significant causes of blindness worldwide is reduced corneal transparency due to improper fibrosis 
after corneal injury or inflammation1. The cornea is mostly made of rigid layers that are interspersed with kerato-
cytes, which are small in size and metabolically quiescent. Stromal extracellular matrix (ECM) layers are formed 
as packed lamellae of arrayed collagen bundles that are aligned and supported by the corneal proteoglycans kera-
tocan2, lumican3,4, decorin5, and mimecan6. This precise arrangement provides transparency for the visual spec-
trum of light, and forms the major refractive curvature of the eye7. To minimize light-scattering by keratocytes, 
these contain high levels of intracellular crystallins8, which include in particular aldehyde dehydrogenase 3A1 
(ALDH3A1)9,10.
During corneal trauma (e.g., wounding, refractive surgery, infection, chemical burn) the keratocytes are 
activated by various growth factors, such as transforming growth factor (TGF)-β 1 and TGF-β 2 and insulin-like 
growth factor (IGF)-1, which promote the sealing of stromal defects. The individual growth factors and their 
interactions in the stroma can critically alter the light diffraction and the clinical outcome.
After IGF-1 receptor activation, the keratocytes transdifferentiate to corneal-wound-type fibroblasts11, which 
express Thy-1 at the cell surface12 and produce proteoglycans and other components of the ECM. In this way, 
some of the intracellular transparency diminishes due to down-regulation of the crystallins11, although this 
scenario yields an ECM that is similar in composition to the normal cornea11,13. In contrast, TGF-β receptor 
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activation leads to corneal fibrosis and a hazed stroma, which results in reduced physiological optical perfor-
mance14–18. TGF-β facilitates differentiation of the keratocytes into myofibroblasts18,19, which are hallmarked 
by the formation of alpha-smooth muscle actin (α -SMA)20 fibers. These cells secrete ECM materials that form 
non-transparent scaffolds of scar collagen21,22. With this TGF-β receptor activation, the proteoglycans that are 
normally scarce in the adult cornea, such as biglycan, are up-regulated23,24, while the expression of keratocan, 
which is normally abundant, is down-regulated25–27. Furthermore, TGF-β down-regulates crystallin expression, 
which increases the light scattering of these cells28.
Guided fibrosis of keratocytes has therefore gained significant interest in recent years, and several molecular 
targets related to fibrosis have been identified. The TGF-β /Smad signaling axis is believed to be one of the main 
TGF-β downstream cascades connected to fibrotic corneal wound healing18,29–31. The activated TGF-β receptor 
complex phosphorylates Smad3, which then functions as a nuclear signal transducer32. Smad7 is then expressed, 
which acts as an antagonist of this TGF-β signal transduction, as part of a negative-feedback loop31,33.
DNA histone acetylation/deacetylation, i.e., epigenetic therapy, has been proposed for the modulation of 
TGF-β –mediated fibrosis34–36. Suberoylanilidehydroxamic acid (SAHA; also known as vorinostat) has been 
demonstrated to be a potent histone deacetylase (HDAC) inhibitor that is safe for application to the ocular sur-
face37. Using rabbits in a corneal haze model, SAHA was validated as an effective inhibitor of post-photorefractive 
keratectomy corneal haze. Furthermore, in-vitro studies on animal and human corneal fibroblast wounding mod-
els have shown disruption of TGF-β –mediated fibrotic responses38,39 and inhibition of Smad2/3 phosphoryla-
tion40,41. SAHA has also been approved for human use for the treatment of cutaneous T-cell lymphoma by the US 
Food and Drug Administration42.
Halofuginone is a natural metabolite from the ‘evergreen hydrangea’ Dichroa febrifuga that has been approved 
for anti-fibrotic therapy in patients with scleroderma by the US Food and Drug Administration43, and it has been 
shown to inhibit the transformation of fibroblasts into myofibroblasts44. Halofuginone inhibits the expression of 
Smad3 and its phosphorylation45,46, with up-regulation of Smad747 and down-regulation of TGF-β 2 receptors48.
Although the effects of SAHA and halofuginone on the TGF-β /Smad pathway in keratocytes have been defined 
to some extent, there remains the need to further optimize wound-healing responses pharmacologically, by aug-
menting the beneficial aspects of the healing, and inhibiting the associated fibrosis and scarring49. Guided fibrosis 
might inhibit some of the vital roles of TGF-β in wound healing, particularly in terms of cell proliferation50. 
Here, IGF-1 might therefore be a suitable additional growth factor to compensate for these effects48,51, while it 
should encourage transdifferentiation of the keratocytes to a more regenerative phenotype–to wound-type cor-
neal fibroblasts11.
This concise report presents the effects of the combination of IGF-1 with the antifibrotics SAHA and halofugi-
none (both approved for human use) on TGF-β 2–activated primary human keratocytes as a cell-culture model of 
corneal stromal wounding. We thus studied TGF-β /Smad signaling and keratocyte proliferation, along with the 
ECM composition and the corneal crystallin ALDH3A1, which are detrimental for corneal transparency.
Results
IGF-1 alone and in combination with SAHA or halofuginone inhibits nuclearization of Smad3 
and modulates Smad7 levels. For the imaging flow cytometry analysis of Smad3 translocation, we ran an 
algorithm for co-localization of nuclear and Smad3 probes in the individual naïve human keratocytes treated and 
analyzed here. As shown in Fig. 1a,b, 70.8% of these keratocytes that were treated with 10 ng/ml TGF-β 2 alone 
(i.e., as positive control; Fig. 1a, CON+ ) promoted translocation of Smad3 to the nucleus, in contrast to the 17.5% 
translocation seen for the naïve keratocytes (i.e., as negative control; Fig. 1a, CON− ). On this background of 
10 ng/ml TGF-β 2, treatment of the keratocytes with only 10 ng/ml IGF-1 led to a 30.0% loss in the Smad3 nucle-
arization compared to the TGF-β 2 positive control (40.8% vs. 70.8%, respectively), indicating the anti-TGF-β 
2 activity of IGF-1 alone (Fig. 1a, IGF-1). The TGF-β 2–treated keratocytes were also treated with 10 nM SAHA 
alone and in combination with 10 ng/ml IGF-1 (Fig. 1a, SAHA, combo SAHA), which showed the lowest levels 
of Smad3 nuclearization, at 6.6% and 9.7%, respectively; i.e., significantly lower than both the TGF-β 2 positive 
control and the negative control (p < 0.001). The TGF-β 2–treated keratocytes were also treated with 5 ng/ml 
halofuginone alone and in combination with 10 ng/ml IGF-1 (Fig. 1a, HAL, combo HAL), which showed similar 
levels of Smad3 nuclearization to the negative control (22.6%, 22.9%, respectively), and were significantly lower 
than the TGF-β 2 positive control (p < 0.001).
This imaging flow cytometry analysis of Smad3 nuclearization thus demonstrated high activity for the 
TGF-β /Smad pathway in the TGF-β 2 positive control, and clear inhibition in these treatment groups. 
Immunoblotting studies of human and canine corneal fibroblasts40,41 have recently shown SAHA-mediated inhi-
bition of Smad2/3 phosphorylation, which might be the main mechanism for the lower nuclearization of Smad3 
observed with these treated keratocytes. Indeed, Smad3 nuclearization was notably decreased by halofuginone, 
in agreement with a report from Nelson et al.45.
Furthermore, imaging flow cytometry analysis was used to determine the median Smad7 fluorescence inten-
sities, which correspond to the intracellular levels of this protein. Significantly higher Smad7 median fluores-
cence intensity was observed for the TGF-β 2 positive control (1.22 × 105, interquartile range, 0.98 × 105; Fig. 2b, 
CON+ ) compared to the negative control (Fig. 2b, CON− ) and all of the treated groups (p < 0.001), which 
testifies to the TGF-β 2 inhibitory transcriptional feedback loop. The TGF-β 2–treated keratocytes that were also 
treated with IGF-1 or halofuginone or their combination (Fig. 2b, IGF-1, HAL, combo HAL) showed similar 
Smad7 median fluorescence intensities to the negative control (Fig. 2b, CON− ; 0.65 × 105, interquartile range, 
0.87 × 105), whereas those also treated with SAHA alone or with the IGF-1 plus SAHA combination (Fig. 2b, 
SAHA, combo SAHA) showed significantly higher Smad7 median fluorescence intensities (0.98 × 105, interquar-
tile range, 1.45 × 105; 1.18 × 105, interquartile range, 1.84 × 105; respectively; p < 0.001).
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This treatment with SAHA resulted in more Smad7, despite the inhibition of Smad3 shown earlier. 
Halofuginone, on the other hand, did not show any significant increase in the intracellular levels of Smad7 com-
pared to the negative control, which is not in agreement with the report of Saika et al.47.
Expression of ALDH3A1 is augmented by the IGF-1 plus SAHA combination. The median 
fluorescence intensity of ALDH3A1 for the negative control (Fig. 3a, CON− ) was 24.7% higher (1.01 × 106, 
interquartile range, 0.67 × 106) compared to the TGF-β 2 positive control (Fig. 3a, CON+ ; 0.81 × 106, interquartile 
range, 0.80 × 106, p < 0.001). IGF-1 treatment of the TGF-β 2–treated keratocytes resulted in a 25.8% increase in 
ALDH3A1 median fluorescence intensity compared to the TGF-β 2 positive control (Fig. 3a, CON+ ). The lower 
levels for the TGF-β 2 positive control correlates to increased cell light scattering in myofibroblasts, which has 
previously been coupled with lower levels of corneal crystallins8,10. The TGF-β 2–treated keratocytes treated with 
IGF-1 in combination with SAHA had similar levels of the corneal crystallin ALDH3A1 to the keratocytes of 
the negative control (Fig. 3a, IGF-1, combo SAHA; p = 0.058, p = 0.454, respectively). Furthermore, the TGF-β 
Figure 1. Smad3 translocation to the nucleus, analyzed using imaging flow cytometry. (a) Relative levels 
of Smad3 nuclearization in human keratocytes. *p < 0.001 compared to CON+ ; **p < 0.001 compared to 
CON+ and CON− (Chi2 tests). (b) Workflow diagram of the IDEAS software. First, images of the keratocytes 
in focus were chosen, and then the relevant cell population was selected, excluding the nonspecific labeling. 
The probe similarity algorithm for co-localization of the nucleus and Smad3 was then defined. The software 
calculated the correlation coefficient (Similarity Dilate) of the two probes, plotted as a frequency histogram. R3, 
keratocytes with Similarity Dilate > 1, which implies nuclearization has occurred. (c) Representative images of 
ketatocytes labeled for Smad3 and the nucleus, as revealed by the imaging flow cytometry (green, AlexaFluor® 
488, Smad3; purple, 7AAD, nucleus). Upper panel, cytosolic Smad3; lower panel, nuclearized Smad3. CON+ , 
positive control of 10 ng/ml TGF-β 2; CON− , negative control for naïve human keratocytes. All of the following 
conditions also included 10 ng/ml TGF-β 2: 10 ng/ml IGF-1; 5 ng/ml halofuginone (HAL); 10 ng/ml IGF-1 plus 
5 ng/ml halofuginone (combo HAL); 10 nM SAHA; 10 ng/ml IGF-1 plus 10 nM SAHA (combo SAHA).
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Figure 2. Intracellular Smad7 levels, analyzed using imaging flow cytometry. Data from imaging flow 
cytometry were first analyzed using the IDEAS software as described in Fig. 1b. (a) Frequency histogram of 
Smad7 fluorescence intensity plotted for each condition. *p < 0.001 compared to CON+ ; ^p < 0.001 compared 
to CON− (Mann-Whitney rank sum tests). (b) Box and whisker plot of Smad7 median fluorescence intensity. 
Horizontal line within box, median fluorescence intensity; boundaries of the box, 25th and 75th percentiles; 
whiskers, boundaries of 5th and 95th percentiles. The median fluorescence intensity can be considered as a 
relative measure of the intracellular Smad7 levels. (c) Representative images of keratocytes labeled for Smad7 
and the nucleus, as revealed by the imaging flow cytometry (blue, Cy5, Smad7; purple, 7AAD, nucleus). For 
details of conditions, see legend to Fig. 1.
Figure 3. Intracellular ALDH3A1 levels, analyzed using imaging flow cytometry. (a) Box and whisker 
plot of ALDH3A1 fluorescence intensity (see also legend to Fig. 2). The median fluorescence intensity can be 
considered as a relative measure of intracellular ALDH3A1 levels. *p < 0.001 compared to CON+ ; ^p < 0.001 
compared to CON− (Mann-Whitney rank sum tests). (b) Representative images of keratocytes labeled for 
ALDH3A1, as revealed using imaging flow cytometry (orange, AlexaFluor® 488, ALDH3A1). For details of 
conditions, see legend to Fig. 1.
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2–treated keratocytes treated with halofuginone alone, the IGF-1 plus halofuginone combination, and SAHA 
alone, all showed lower ALDH3A1 levels (Fig. 3a, HAL, combo HAL, SAHA), and were similar to the TGF-β 2 
positive control.
IGF-1 and SAHA, alone and in combination, regulate the secretion of keratocan and biglycan. 
Compared to the TGF-β 2–treated keratocytes of the positive control (Fig, 4a, CON+ ), the keratocan levels in 
the culture supernatants were significantly higher for all of the further additions (Fig. 4a; p < 0.001), except for 
the treatments that included halofuginone (Fig. 4a, HAL, combo HAL). On the other hand, the biglycan levels 
were significantly reduced compared to the TGF-β 2–treated keratocytes under all of these conditions (Fig. 4b, 
p < 0.001), except for the IGF-1 plus halofuginone combination (Fig. 4b, combo HAL). Biglycan is normally not 
present in the corneal stroma, and it is seen only for a disorganized ECM; i.e., in a corneal scar. However, along 
with other proteoglycans, keratocan is responsible for precise collagen fibril alignment in the normal cornea7. For 
the TGF-β 2–treated keratocytes there was a 38.0% ± 4.3% decrease in keratocan secretion and a 45.5% ± 7.2% 
increase in biglycan secretion compared to the negative control. The profiles of these proteoglycans were mainly 
influenced by SAHA addition to these TGF-β 2–treated keratocytes. Here, 10 nM and 5 nM SAHA were used alone 
and in the combination with 10 ng/ml IGF-1 (Fig. 4a,b, SAHA, combo SAHA), which resulted in increases for 
keratocan secretion of 83.7% ± 11.8%, 48.5% ± 4.7%, and 48.3% ± 1.9%, respectively, and in decreases for bigly-
can secretion of 79.4% ± 6.6%, 86.6% ± 1.8%, and 63.4% ± 10.6%, respectively, compared to the TGF-β 2 positive 
control. The TGF-β 2–treated keratocytes treated with SAHA in combination with IFG-1 had similar expression 
profiles of these proteoglycans to the negative-control keratocytes (Fig. 4a,b, combo SAHA, CON− ).
Inhibition of keratocyte transdifferentiation into myofibroblasts. These human keratocyte cultures 
contained dendritic cells that have little cytoplasm, and that stain positive for keratocan and negative for α -SMA 
fibers. Under the stimulation with TGF-β 2, these keratocytes transdifferentiated into myofibroblasts, with a gain 
in cell volume and the formation of α -SMA stress fibers (Fig. 5a,b and Supplementary Fig. S1).
We used confocal microscopy to simultaneously analyze the expression of Thy-1 and the formation of α -SMA 
fiber bundles, which allowed us to roughly differentiate between keratocytes, wound-type corneal fibroblasts, and 
corneal myofibroblasts. The TGF-β 2–treated keratocytes of the positive control showed Thy-1–positive cells with 
α -SMA stress fibers, namely myofibroblasts (Fig. 5, CON+ ), while in the negative-control naïve human kerat-
ocytes there was very little Thy-1 labeling and only the diffuse presence of α -SMA in the cells (Fig. 5, CON− ). 
This diffuse α -SMA corresponded to the observations of unstructured actin in keratocytes reported previously52. 
When SAHA or halofuginone were added to the TGF-β 2–treated keratocytes in the wound model, the myofi-
broblastic phenotype was less common, although the cells were more spindle shaped and larger, compared to the 
negative control (Fig. 5, SAHA, HAL). Thy-1 was very prevalent in the TGF-β 2–treated keratocytes with SAHA, 
and less so with the halofuginone treatments, where the α -SMA stress fibers were less prominent than in the 
TGF-β 2–treated keratocytes of the positive control. In the presence of Thy-1, this indicates fibroblastic transdif-
ferentiation, as opposed to myofibroblastic transdifferentiation12.
The combination of IGF-1 plus halofuginone, but not SAHA, increases keratocyte proliferation. 
The proliferative activity of the TGF-β 2–treated keratocytes was determined after 48 h of treatment, using the 
crystal violet assay (Fig. 6, CON+ ). This positive control was not significantly diminished in the keratocytes 
treated with SAHA and halofuginone, as also for the negative control (Fig. 6); indeed, the TGF-β 2–treated kerat-
ocytes that were also treated with 5 ng/ml halofuginone alone and in combination with 10 ng/ml IGF-1 showed 
enhanced proliferation (Fig. 6, HAL, combo HAL). The combination of 10 nM SAHA with 10 ng/ml IGF-1 
showed proliferation rates that were not significantly different from that of the TGF-β 2 positive control (Fig. 6, 
combo SAHA, CON+ ). Both concentrations of IGF-1 used alone (Fig. 6, 5 ng/ml, 10 ng/ml) with the TGF-β 2–
treated keratocytes demonstrated significantly increased proliferation compared to both the TGF-β 2 positive con-
trol and the negative control (p < 0.001), with no significant difference seen between these IGF-1 concentrations.
Figure 4. Secretion of keratocan (KERA, a) and biglycan (BIG, b), as analyzed using ELISAs. Mean relative 
ratios (%, ± SD) of absorbance at 590 nm in cell culture supernatants. *p < 0.001 compared to CON+ 
(ANOVA). For details of conditions, see legend to Fig. 1.
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Figure 5. Representative microscopy images of human corneal stromal cells activated by TGF-β2 (corneal 
stromal wound model), and under treatments as defined in the legend to Fig. 1. (a) Laser scanning confocal 
microscopy of transdifferentiation of keratocytes to myofibroblasts after exposure to 10 ng/ml TGF-β 2, showing 
labeling of α -SMA (green, AlexaFluor® 488) and nuclei (red, DAPI). (b) Phase-contrast light microscopy of 
isolated primary human corneal keratocytes and corneal myofibroblasts after exposure to 10 ng/ml TGF-β 2. 
(c,d) Representative laser scanning confocal microscopy images following treatments of keratocytes as detailed 
in legend to Fig. 1, showing labeling of Thy-1 (blue, PE/Cy5® ), α -SMA (green, FITC), and nuclei (red, DAPI). 
Scale bars, 100 μ m. Images are representative of three independent experiments.
www.nature.com/scientificreports/
7Scientific RepoRts | 6:34373 | DOI: 10.1038/srep34373
Discussion
Keratocytes have a unique role in vision, as they sustain the corneal stroma and maintain corneal transparency, 
and they have can provide injury repair, and return the corneal stroma to its non-opaque normalcy. The loss of 
stromal transparency during wound healing has been linked to myofibroblast transdifferentiation, and thereby to 
errant ECM production and increased intracellular light scattering. The in-vitro data from the present study indi-
cate that these reference antifibrotic compounds that are approved for human use (i.e., SAHA and halofuginone) 
can provide beneficial influence over the corneal stromal healing process, especially when combined with IGF-1. 
They thus favor a non-scarring healing pathway, while propagating elements of transparency.
The canonical Smad signaling pathway of TGF-β 2 was successfully inhibited by SAHA and halofuginone 
in the present study. IGF-1 alone decreased Smad3 nuclearization, which is a novel finding for human kerato-
cytes. The combination of IGF-1 with these well-established antifibrotics, SAHA and halofuginone, yielded more 
pronounced block of the TGF-β 2–promoted translocation. Inhibition of Smad3 phosphorylation might be the 
main mechanism behind this effect40. Smad7 is an inhibitory feedback transducer, and as such, it also inhibits 
phosphorylation of Smad3, as has been shown in corneal wounding models31,40,47. According to the present study, 
SAHA appears to have effects through a separate mechanism, by which it causes higher levels of Smad7 even 
though it decreases the transcriptional activity of TGF-β 2. It has been reported that proteasome-mediated degra-
dation of Smad7 depends upon a balance between acetylation, deacetylation, and ubiquitination53. HDACs tend 
to deacetylase Smad7 and to decrease its stability, thus channeling it toward ubiquitination and degradation54. We 
suggest that as an HDAC inhibitor, SAHA disrupts the activity of specific HDACs, thereby preventing the degra-
dation of Smad7 in the cytosol, and apparently promoting greater inhibition of fibrosis through the TGF-β /Smad 
pathway (see schematic representation in Fig. 7).
This study of Smad3 and Smad7 has provided relevant insight into TGF-β /Smad signaling, and it has shown 
that the antifibrotic compounds investigated (i.e., SAHA and halofuginone) inhibit this pathway to a significant 
extent. Furthermore, it has demonstrated that addition of IGF-1 inhibits translocation of Smad3 to the nucleus 
in its own right, with these effects potentiated when combined with SAHA (Fig. 7). This is the first study to show 
that IGF-1 can inhibit Smad3 translocation to the nucleus in human keratocytes. However, we did not inves-
tigate directly other intracellular pathways here, which can also propagate some of the TGF-β signals, such as 
mitogen-activated protein kinase55 and the Rho family proteins, which might take part in this system.
Figure 6. Crystal violet proliferation assay. (a) Proliferation rates of the keratocytes under treatments as 
defined in legend to Fig. 1, as revealed by crystal violet assays. *p < 0.001 compared to CON− ; **p < 0.001 
compared to CON+ and CON− (ANOVA). For details of conditions, see legend to Fig. 1. (b) Representative 
phase-contrast light microscopy image of keratocytes after treatment with crystal violet, before photometric 
measurements.
www.nature.com/scientificreports/
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The imaging flow cytometry analysis performed here was applied to large numbers of cells (n = 3000), where 
each individual cell was taken into account. Thus, rather than using a generalization based upon population 
means for gene expression or proteome investigation, the events of Smad3 nuclearization in each individual cell 
were viewed and analyzed; i.e., using a single-cell approach. According to the literature, the present study is the 
first to use imaging flow cytometry for the characterization of intracellular events in keratocytes.
The IDEAS analysis software was used here to measure the fluorescence of the specific antibodies that were 
bound to the target proteins, with the calculation of the median fluorescence intensities, and thus the relative 
levels of these target proteins (see Methods). All of the keratocytes were prepared under the same conditions 
and were measured with identical machine calibration in a single day. The weakness of quantitative analysis of 
immunofluorescence using flow cytometry is the wide dispersion of the data obtained, which here were carefully 
weighted with the calculation of the median fluorescence intensities and the use of box and whisker plots. This 
approach for the examination of cell cultures at the subcellular level using imaging flow cytometry analysis as the 
first experimental step for the validation of a therapy was recently verified56,57.
While with flow cytometry the native shape of cells is lost, confocal fluorescence microscopy provided the 
proof-of-concept here, as an additional insight into the differentiation of these keratocytes. Hassell and Birk11 reported 
that wound-type fibroblasts have the most important role in regenerative wound healing in vivo, while myofibroblasts 
lead to erroneous ECM formation and scarring. In the present study, IGF-1 and the selected antifibrotics prevented 
this transdifferentiation to myofibroblasts, with higher proportions of Thy-1-positive wound-type fibroblasts in this 
cell-culture model of corneal stromal wounding, which would favor the regenerative pathway of wound healing11,12.
A crystallin (i.e., ALDH3A1) and two proteoglycans (i.e., keratocan, biglycan) were studied here, which have 
been shown to be representative of intracellular and ECM transparency, respectively8,11. Differences in the crys-
tallin levels were shown under the different stimulation conditions, where the lowest levels were seen for the 
TGF-β 2–treated keratocytes of the positive control, with a prevalence of myofibroblasts in the immunofluorescent 
microscopy. All of the treatments inhibited this TGF-β 2–promoted depletion of ALDH3A1 in the cytosol to some 
extent, although significant inhibition was only achieved by IGF-1 alone and in combination with SAHA. The 
levels of the crystallin in the other treated keratocytes were significantly lower compared to the negative control, 
which confirms previous findings that the expression of ALDH3A1 is lower in transdifferentiated fibroblasts than 
in native keratocytes11,58. Furthermore, the keratocytes in the ELISA for the two proteoglycans saw the secretion 
of the highest levels of keratocan and the lowest levels of biglycan under the treatments with SAHA and IGF-1 and 
their combination, which indicates that under these conditions the ECM should appear more transparent in vivo.
The secretion of keratocan was significantly increased by IGF-1 alone, which has also been reported for 
lumican13, both of which are significant structural proteoglycans in terms of a transparent collagenous ECM. 
Furthermore, IGF-1 promoted a beneficial increase in cytosolic ALDH3A1, which to the best of our knowledge 
has not been reported in previous studies. The decreased TGF-β 2–promoted Smad3 nuclearization that was seen 
here for IGF-1 was previously suggested in studies of muscle fibrosis59,60 and prostate cancer61, but to date this 
has not been shown for human keratocytes. Similar to previous in-vitro studies in corneal wound healing51, the 
confocal microscopy in the present study indicated that TGF-β 2–promoted transdifferentiation to myofibroblasts 
is less likely to occur with the addition of IGF-1. As demonstrated by the proliferation assays here, the TGF-β 
2–promoted proliferation rates under IGF-1 treatment of the keratocytes was significantly increased, which cor-
responds to a report of exogenous IGF use on human corneal fibroblasts51. We can deduce here that IGF-1 alone 
can decrease the probability of corneal stromal scar formation, while exerting its well-known positive effects on 
Figure 7. Schematic representation of the inhibitory effects of IGF-1, suberanilohydroxamic acid (SAHA) 
and halofuginone (HAL) on the TGF-β pathway in keratocytes. As shown with imaging flow cytometry, IGF-
1, SAHA and halofuginone block Smad3 translocation to the nucleus. Inhibitory Smad7 forms as a negative-
feedback loop53, blocking Smad3 phosphorylation and nuclearization. SAHA can also inhibit HDACs, which 
leads to acetylation and subsequent ubiquitination of Smad754, resulting in higher intracellular Smad7 levels, as 
observed in the present study. P, phosphate group; UB, ubiquitin; HDAC, histone deacetylase.
www.nature.com/scientificreports/
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keratocyte proliferation and wound repair. Hence, IGF-1 is not only a valid aid to inhibitors of the TGF-β /Smad 
pathway in keratocytes, but it can act alone as a potent modulator of fibrosis.
Although our study indicates the need for further investigations and in-vivo validation to confirm these data, 
it appears that IGF-1 supplemented with SAHA and halofuginone can be advocated for anti-fibrotic therapy of 
corneal wounding.
Methods
Isolation and cultivation of primary human corneal keratocytes. The human keratocytes used in 
this study were isolated and cultured in serum-free medium according to a modified procedure described by 
Jester et al.62 and Pei et al.10. Briefly, corneal tissue was harvested from donor corneas that are normally discarded 
during the standard surgical procedure for perforative keratoplasty. Written informed consent for perforative ker-
atoplasty was obtained. The Slovenian National Ethics Committee approved the collection of these tissue samples 
(No. 132/11/13, 20.12.2013), furthermore, our study was done in accordance with the Declaration of Helsinki and 
the Oviedo Convention. The corneal epithelium and Descemet’s membrane with the endothelium were scraped 
off using a hockey knife, while the remaining stroma was stored in sterile advanced Dulbecco’s modified Eagle’s 
medium (DMEM; Life Technologies Ltd, Paisley, UK). The tissue was cut into blocks and incubated at 37 °C 
overnight in 2.0 mg/ml collagenase type I (Sigma-Aldrich, Grand Island, USA) diluted in DMEM. The digested 
material was collected and centrifuged in a 50-ml tube at 200 × g for 5 min, to obtain the pellet of primary human 
keratocytes. Some of these cell pellets were frozen in liquid nitrogen and stored at − 80 °C until analysis. These 
isolated cells were washed in DMEM and cultured under serum-free conditions with the addition of 100 U/ml 
penicillin, 1 mg/ml streptomycin, and 2 mM L-glutamine. The cells were resuspended and transferred into col-
lagen-coated tissue culture flasks for further cultivation at 37 °C and in an atmosphere of 5% CO2. After 48 h, the 
non-adherent cells were removed and the adherent cells were cultured further. At the time of the experiments, 
these human keratocytes had reached 3–6 passages.
TGF-β2 activation and treatment with IGF-1 and the antifibrotics. The human keratocytes were cul-
tured in serum-free medium as described above (with the negative control as the untreated human keratocytes). 
First, the upper concentrations of the reference bioactives were set according to the 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) cell-viability assay (see Supplementary Fig. 2). A reductionist corneal stro-
mal wounding model was initiated by addition of 10 ng/ml TGF-β 215 (R&D systems, Minneapolis, USA) into the 
DMEM for 48 h (as the positive control). These ‘activated keratocytes’ were also treated with the different bioactives, 
which were added at the time of the ‘wounding’, with parallel incubation of the wound model for 48 h, due to the 
fast transient nature of these keratocytes. The bioactives used were: 10 ng/ml, 5 ng/ml recombinant IGF-1 (R&D 
systems, Minneapolis, USA), 10 ng/ml, 5 ng/ml halofuginone (Santa Cruz Biotechnology, Heidelberg, Germany), 
and 10 nM, 5 nM SAHA (Tocris Bioscience, Bristol, UK). The 10 ng/ml IGF-1 was also tested in combination with 
one concentration of each of the antifibrotics: 10 ng/ml halofuginone, and 10 nM SAHA. After completion of the first 
proliferative assays, the concentrations of halofuginone and SAHA used for the further experiments were chosen 
as 5 ng/ml and 10 nM, respectively. These human keratocytes were also used for further testing, as described below.
Analysis of the TGF-β/Smad signaling pathway using imaging flow cytometry. To quantita-
tively determine Smad7 expression and the rate of Smad3 nuclear translocation, these human keratocytes were 
analyzed using multispectral imaging flow cytometry (ImageStreamX; Amnis Coorporation, Seattle, USA). The 
keratocytes were harvested, followed by their permeabilization, with the following antibodies used for the stain-
ing, according to manufacturer protocols: mouse anti-Smad7 or rabbit anti-Smad3 antibodies, with Cy5 goat 
anti-mouse or goat AlexaFluor® 488 anti-rabbit secondary antibodies (Abcam, Cambridge, UK), and 7AAD (BD 
Pharminogen) to visualize the nucleus. Cell images were acquired for 3000 events per sample at 40x magnifica-
tion, using 488 nm and 658 nm lasers lines, with the fluorescence collected using two spectral detection channels. 
For double-stained keratocytes, two single-stained controls were used to compensate for the fluorescence between 
the channel images. The cell images were analyzed using the IDEAS image-analysis software (Amnis). First, cells 
within the focal plane were selected using a plot of the image contrast versus the root-mean-squared gradient. 
Then the aspect ratio versus the cell area was gated to isolate populations of single cells on a bivariate plot57. The 
Smad7 probe median fluorescence intensities were determined for the relative intracellular quantification. The 
Smad3 nuclear translocation was calculated with a similarity algorithm (similarity dilate), where the software 
compared the location of the Smad3 versus the location of the nucleus. The subpopulation of keratocytes in which 
Smad3 translocation occurred were calculated and expressed as percentages56.
Measurement of intracellular ALDH3A1 using imaging flow cytometry. The human keratocytes 
were harvested, permeabilized, and treated with a rabbit anti-ALDH3A1 antibody labeled with a AlexaFluor® 
488 goat anti-rabbit antibody (Abcam), according to the manufacturer protocols. 7AAD (BD Pharminogen, 
Heidelberg, Germany) was used for nuclear staining. The keratocyte images were obtained using imaging flow 
cytometry and the IDEAS software, as described above. For the relative quantification, the median fluorescence 
intensities of ALDH3A1 were determined.
Evaluation of keratocan and biglycan secretion using enzyme-linked immunosorbent 
assays. The human keratocytes were seeded at 10,000 cells/well in 96-well plates. They were treated as 
described above, and after 48 h the levels of keratocan and biglycan in the supernatants were determined using 
ELISA kits (Invitrogen Co., Camarillo, USA, and USC Life Science Inc., Wuhan, China), based on the manufac-
turer protocols. All of these assays were performed in triplicate.
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Confocal fluorescence microscopy. The human keratocytes were immunostained with antibodies against 
Thy-1 and α -SMA, as previously described12. Briefly, the keratocytes were grown on collagen-coated 8-well glass 
chamber slides for 24 h until the respective treatments, as described above. After 48 h, they were fixed in 2% 
paraformaldehyde in phosphate-buffered saline (pH 7.4). They were then permeabilized and reacted with a PE/
Cy5-conjugated anti-human Thy-1 antibody (Abcam) and a FITC-conjugated anti-human α -SMA antibody 
(Abcam), according to manufacturer protocols. The samples were counter-stained for the nucleus, and mounted 
with FluoroshieldTM with DAPI (Sigma-Aldrich). These keratocytes were then evaluated using laser-scanning 
confocal microscopy (Leica TCS SP5 II; Leica Microsystems, Mannheim, Germany).
Cell proliferation. To perform the cell proliferation assays, the human keratocytes were seeded at 10,000 
cells/well in 96-well plates, at a concentration of 30 viable cells per well. After adding TGF-β 2 and the various 
treatments, as described above, the cells were stained with crystal violet and the absorbance was measured at 
595 nm. All of these cell proliferation assays were carried out in triplicate.
Statistical analysis. The data were collected and analyzed using Statistical Package for Social Sciences (SPSS), 
version 16. The data are expressed as the means ± SD for the parametric tests, and median ± interquartile range for 
non-parametric tests. Data normality was analyzed using Shapiro-Wilk tests. Comparison of groups were performed 
using one-way ANOVA for multiple comparisons, followed by Holm-Sidak post-hoc analysis or Mann-Whitney 
rank sum tests for comparisons of medians. Chi2 tests were used to analyze the significance of the Smad3 nuclear 
translocation. The differences were considered statistically significant for p < 0.001, with a 95% confidence interval.
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